secwatch / observer
8-K filed January 26, 2026, 6:59 PM ET ticker INDV CIK 0001625297
other material confidence high sentiment neutral materiality 0.75

Indivior Pharmaceuticals, Inc. (INDV): M&A transaction — Indivior completes U.S. Domestication; begins trading on Nasdaq as Delaware corp under INDV

Indivior Pharmaceuticals, Inc.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Indivior Pharmaceuticals, Inc.: Adopted Bylaws in connection with U.S. Domestication.

Change
bylaw amendment
Exact text from the filing
Indivior U.S. adopted Bylaws, a copy of which is attached hereto as Exhibit 3.2 (the “ Bylaws ”).
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Indivior Pharmaceuticals, Inc.: Adopted Global Code of Conduct and Code of Ethics for Senior Financial Officers (effective 2026-01-26).

Change
code of ethics
Effective
2026-01-26
Exact text from the filing
Effective January 26, 2026, Indivior U.S. adopted a Global Code of Conduct which applies to all directors, officers, and employees of Indivior U.S., and a Code of Ethics for Senior Financial Officers, each of which are substantially the same as those of Indivior U.K.
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Indivior Pharmaceuticals, Inc. underwent a change of control involving Indivior PLC (closed 2026-01-23).

Action
change of control
Counterparty
Indivior PLC
Closing
2026-01-23
Exact text from the filing
ncorporation) (Commission File Number) (IRS Employer Identification No.) 10710 Midlothian Turnpike , Suite 125 North Chesterfield , VA 23235 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: 804 - 379-1040 Indivior PLC (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Indivior Pharmaceuticals, Inc. amended First Amendment to Note Purchase Agreement with RBP Global Holdings Limited, Piper Sandler Finance LLC, as Administrative Agent and the lenders from time to time party thereto (effective 2026-01-26).

Action
amendment
Agreement
notes offering
Counterparty
RBP Global Holdings Limited, Piper Sandler Finance LLC, as Administrative Agent and the lenders from time to time party thereto
Effective
2026-01-26
Exact text from the filing
Amendment to Note Purchase Agreement Effective January 26, 2026, following the effectiveness of the U.S. Domestication, RBP Global Holdings Limited, Piper Sandler Finance LLC, as Administrative Agent and the lenders from time to time party thereto entered into that certain First Amendment to Note Purchase Agreement with respect to the Note Purchase Agreement, dated as of November 4, 2024 (the “Note Purchase Agreement”)
View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Indivior Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-021660
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.